Dissolvable microarray patches of levodopa and carbidopa for Parkinson’s disease management

Qonita Kurnia Anjani, Natalia Moreno-Castellanos, Yaocun Li, Akmal Hidayat Bin Sabri, Ryan F. Donnelly*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

23 Downloads (Pure)


Carbidopa and levodopa remain the established therapeutic standard for managing Parkinson’s disease. Nevertheless, their oral administration is hindered by rapid enzymatic degradation and gastrointestinal issues, limiting their efficacy, and necessitating alternative delivery methods. This work presents a novel strategy employing dissolving microarray patches (MAPs) loaded with carbidopa and levodopa, formulated with Tween® 80 to improve their transdermal delivery. The fabricated MAPs demonstrated an acceptable mechanical strength, resisting pressures equivalent to manual human thumb application (32 N) onto the skin. Additionally, these MAPs exhibited an insertion depth of up to 650 µm into excised neonatal porcine skin. Ex vivo dermatokinetic studies could achieve delivery efficiencies of approximately 53.35 % for levodopa and 40.14 % for carbidopa over 24 h, demonstrating their significant potential in drug delivery. Biocompatibility assessments conducted on human dermal fibroblast cells corroborated acceptable cytocompatibility, confirming the suitability of these MAPs for dermal application. In conclusion, dissolving MAPs incorporating carbidopa and levodopa represent a promising alternative for improving the therapeutic management of Parkinson’s disease.

Original languageEnglish
Article number114304
Number of pages9
JournalEuropean Journal of Pharmaceutics and Biopharmaceutics
Early online date25 Apr 2024
Publication statusPublished - Jun 2024


  • Parkinson’s disease
  • Dissolving microarray patches
  • Levodopa
  • Carbidopa
  • Microneedles


Dive into the research topics of 'Dissolvable microarray patches of levodopa and carbidopa for Parkinson’s disease management'. Together they form a unique fingerprint.

Cite this